Trial · NCT02028676
Trial comparisons22
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
1 to 20 of 22
Download this page as JSON| Comparison | Source |
|---|---|
| Continued Cotrimoxazole Prophylaxis vs Stopped Cotrimoxazole Prophylaxis: Cotrimoxazole: New WHO Stage 3 or 4 Event or Death | Trial comparisons |
| Continued Cotrimoxazole Prophylaxis vs Stopped Cotrimoxazole Prophylaxis: Cotrimoxazole: New WHO Stage 4 Event or Death | Trial comparisons |
| Once-daily ABC+3TC vs Twice-daily ABC+3TC: Once Versus Twice Daily Abacavir+Lamivudine: All-cause Mortality | Trial comparisons |
| Continued Cotrimoxazole Prophylaxis vs Stopped Cotrimoxazole Prophylaxis: Cotrimoxazole: New Grade 3 or 4 Adverse Event (AE), Not Solely Related to HIV | Trial comparisons |
| Once-daily ABC+3TC vs Twice-daily ABC+3TC: Once Versus Twice Daily Abacavir+Lamivudine: New WHO Stage 3 or 4 Event or Death | Trial comparisons |
| Continued Cotrimoxazole Prophylaxis vs Stopped Cotrimoxazole Prophylaxis: Cotrimoxazole: New WHO Stage 3 Severe Recurrent Pneumonia or Diarrhoea | Trial comparisons |
| Once-daily ABC+3TC vs Twice-daily ABC+3TC: Once Versus Twice Daily Abacavir+Lamivudine: New WHO Stage 4 Event or Death | Trial comparisons |
| Once-daily ABC+3TC vs Twice-daily ABC+3TC: Once Versus Twice Daily Abacavir+Lamivudine: New Grade 3 or 4 Adverse Event (AE), Not Solely Related to HIV | Trial comparisons |
| Clinically Driven Monitoring (CDM) vs Laboratory Plus Clinical Monitoring (LCM): LCM vs CDM: New Grade 3 or 4 Adverse Event (AE), Not Solely Related to HIV | Trial comparisons |
| Once-daily ABC+3TC vs Twice-daily ABC+3TC: Once Versus Twice Daily Abacavir+Lamivudine: New Serious Adverse Events Not Solely Related to HIV | Trial comparisons |
| Continued Cotrimoxazole Prophylaxis vs Stopped Cotrimoxazole Prophylaxis: Cotrimoxazole: New Severe Pneumonia | Trial comparisons |
| Clinically Driven Monitoring (CDM) vs Laboratory Plus Clinical Monitoring (LCM): LCM vs CDM: Disease Progression to a New WHO Stage 4 Event or Death | Trial comparisons |
| Once-daily ABC+3TC vs Twice-daily ABC+3TC: Once Versus Twice Daily Abacavir+Lamivudine: Suppression of HIV RNA Viral Load 96 Weeks After Randomisation | Trial comparisons |
| Continued Cotrimoxazole Prophylaxis vs Stopped Cotrimoxazole Prophylaxis: Cotrimoxazole: All-cause Mortality | Trial comparisons |
Once-daily ABC+3TC vs Twice-daily ABC+3TC: Once Versus Twice Daily Abacavir+Lamivudine: New Grade 3 or 4 Adverse Event (AE), Not Solely Related to HIV, Judged Definitely/Probably or Uncertain Whether Related to Lamivudine or Abacavir | Trial comparisons |
| Continued Cotrimoxazole Prophylaxis vs Stopped Cotrimoxazole Prophylaxis: Cotrimoxazole: New Hospitalisation or Death | Trial comparisons |
| Continued Cotrimoxazole Prophylaxis vs Stopped Cotrimoxazole Prophylaxis: Cotrimoxazole: New Serious Adverse Events Not Solely Related to HIV | Trial comparisons |
| Clinically Driven Monitoring (CDM) vs Laboratory Plus Clinical Monitoring (LCM): LCM vs CDM, Induction ART: Cessation of First-line Regimen for Clinical/Immunological Failure | Trial comparisons |
| Once-daily ABC+3TC vs Twice-daily ABC+3TC: Once Versus Twice Daily Abacavir+Lamivudine: Suppressed HIV RNA Viral Load 48 Weeks After Randomisation | Trial comparisons |
| Continued Cotrimoxazole Prophylaxis vs Stopped Cotrimoxazole Prophylaxis: Cotrimoxazole: New Clinical and Diagnostic Positive Malaria | Trial comparisons |
trials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02028676/comparisons